Status and phase
Conditions
Treatments
About
This study is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety of and immune response to CodaVax-RSV in healthy children. They will be vaccinated in spring to early autumn 2023 and followed through the 2023-24 RSV season. 18 children aged 2 to 5 years who are RSV-seropositive (have antibodies to RSV) and 33 children aged 6 months to < 2 years who are RSV-seronegative (do not have antibodies to RSV) will be enrolled in escalating-dose cohorts. A safety committee will review the safety profile of each dosing group before the next dose-escalation. Children will receive 2 doses of the vaccine at one of several dose levels or placebo (saline solution with no active ingredient) as nose drops; doses will be 28 days apart.
A parent/guardian will record temperature and other conditions in a diary daily for 7 days after each dose. The parent/guardian will be contacted by telephone on the day after Dose 1 for safety assessment and review of the diary data. Children will return to the clinic 3, 7, 14, and 28 days after each dose. The parent/guardian will then be contacted by telephone monthly until 1 year after the second dose.
Study procedures include physical examinations, vital signs, and collections of blood and nose/throat swab samples to look at safety of the vaccine and to analyze body's immune response.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age at the time of informed consent:
RSV Status at Screening:
Good general health status
Product of normal full-term pregnancy (36 to 42 weeks gestation)
Exclusion criteria
Household contact with any of the following groups of individuals for the period up to 14 days after each dose:
Pregnant women
Infants < 6 months of age
With hospitalization for asthma or other chronic respiratory disease in the past 5 years
Immunocompromised individuals, which includes, but is not limited to, those with the following conditions:
Enrolled in the same classroom at full-time day care with infants < 6 months of age for 14 days after each dose
Household contact of another child enrolled into the study
Inadequate venous access for repeated phlebotomy
Height and weight ≤ 5th percentile for age and sex (according to CDC growth charts for children in Part A, according to World Health Organization Child Growth Standards for children in Part B)
Primary purpose
Allocation
Interventional model
Masking
51 participants in 5 patient groups, including a placebo group
Loading...
Central trial contact
Clinical Operations
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal